Woman smiling in a field Woman smiling in a field

For eligible adults with newly diagnosed FLT3-ITD+ AML, Only VANFLYTA®
(quizartinib)
specifically targets
the FLT3-ITD mutation

VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a
FLT3-ITD mutation.

VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant.

Mutations in AML

What is AML?

Find out more about your or your loved one’s disease and the FLT3-ITD mutation

Doctor reviewing data with two adults

Taking
VANFLYTA

Learn how VANFLYTA is taken

Daiichi Sankyo Support portrayal

Find
support

Discover how Daiichi Sankyo may be able to assist you throughout VANFLYTA treatment